Evolving trends in mAb production processes.

Area of Science:

• Biopharmaceutical Manufacturing
• Bioprocessing Engineering
• Antibody Therapeutics

Background:

• Monoclonal antibodies (mAbs) are a leading biopharmaceutical therapeutic class.
• Robust manufacturing platforms are critical for successful antibody drug development and commercialization.
• Current mAb production faces pressures from biosimilars and the need for cost-effective, globalized manufacturing.

Purpose of the Study:

• To discuss the key drivers influencing the evolution of monoclonal antibody (mAb) manufacturing processes.
• To highlight emerging trends in bioprocessing that address current industry needs.
• To analyze the impact of these drivers and trends on mAb production strategies.

Main Methods:

• Review of current trends and drivers in biopharmaceutical manufacturing.
• Analysis of process platform evolution in response to industry demands.
• Discussion of alternative expression systems, continuous biomanufacturing, and non-chromatographic separations.

Main Results:

• Biosimilar market entry necessitates lower cost of goods and globalized manufacturing strategies.
• High-titer monoclonal antibody (mAb) production in mammalian cell culture is now standard.
• Significant evolution in process platform approaches and bioprocessing trends are evident.

Conclusions:

• Key drivers such as biosimilars and high titers are reshaping mAb manufacturing.
• Emerging bioprocessing trends like continuous manufacturing and alternative expression systems are critical for future antibody production.
• Adaptation of manufacturing processes is essential for continued success in the biopharmaceutical therapeutics market.